Leerink Partnrs Issues Positive Outlook for Adagene Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share (EPS) estimate for Adagene to ($0.15), up from the previous estimate of ($0.18), maintaining a "Strong-Buy" rating on the stock.
• Adagene's current full-year EPS estimate is projected at ($0.60), with further estimates suggesting an increasing trend towards profitability in subsequent years.
• The stock price of Adagene has experienced a 14.6% increase recently, with current trading at $2.30, compared to a 12-month low of $1.33.

Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) - Stock analysts at Leerink Partnrs boosted their Q3 2025 earnings estimates for Adagene in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($0.15) per share for the quarter, up from their prior forecast of ($0.18). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Adagene's current full-year earnings is ($0.60) per share. Leerink Partnrs also issued estimates for Adagene's Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.63) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at ($0.43) EPS.

Several other equities analysts also recently issued reports on ADAG. Leerink Partners assumed coverage on shares of Adagene in a report on Wednesday, August 6th. They set an "outperform" rating and a $7.00 price target for the company. HC Wainwright decreased their target price on shares of Adagene from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Adagene currently has an average rating of "Buy" and a consensus target price of $7.00.

Adagene Stock Up 5.6%

Adagene stock traded up $0.11 during mid-day trading on Friday, reaching $2.07. The company's stock had a trading volume of 255,023 shares, compared to its average volume of 68,211. The business has a 50 day moving average price of $1.94 and a 200-day moving average price of $1.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.30 and a current ratio of 2.29. Adagene has a twelve month low of $1.3250 and a twelve month high of $3.5807.

Institutional Investors Weigh In On Adagene

Institutional investors and hedge funds have recently bought and sold shares of the business. Gordian Capital Singapore Pte Ltd acquired a new stake in Adagene in the 1st quarter valued at about $29,000. Marex Group plc acquired a new stake in Adagene in the 2nd quarter valued at about $47,000. Fifth Lane Capital LP purchased a new stake in Adagene during the fourth quarter valued at about $54,000. Finally, Kamunting Street Capital Management L.P. purchased a new stake in Adagene during the fourth quarter valued at about $251,000. 9.51% of the stock is owned by institutional investors and hedge funds.

About Adagene

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.